Drug Profile
Research programme: histamine H4 receptor antagonists - Johnson and Johnson
Alternative Names: Histamine H4 antagonists - JNJPRD; JNJ-10191584; JNJ-7777120; VUF 6002Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Benzimidazoles; Indoles; Piperazines
- Mechanism of Action Histamine H4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Atopic dermatitis; Pruritus; Respiratory tract disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pruritus in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in USA